A mathematical model analyzing the expression hierarchy of three validated glioma antigens (HER2, IL13Rα2, and EphA2) predicted an increased likelihood of tumor elimination when any two of these three antigens are targeted (59). This evidence concerns the gene ERBB2 and central nervous system cancer.